On July 30, biontech (BNTX.US) announced that the phase II clinical trial of tumor mRNA vaccine bnt111+PD-1 combination therapy for unresectable stage III or IV and PD-1 treated progressed melanoma has achieved ORR main endpoint.
On July 30, biontech (BNTX.US) announced that the phase II clinical trial of tumor mRNA vaccine BNT111+PD-1 combination therapy for unresectable stage III or IV and PD-1 treated progressed melanoma has achieved ORR main endpoint. Compared with historical data, the improvement is significant. Biontech and its partner Regeneron plan to present specific data at future medical conferences.
Biontech has a wide range of layouts in the field of tumors, and therapeutic vaccines for tumors are one of the focuses. On the one hand, just like Moderna, biontech has also laid out personalized neoantigen mRNA vaccines (BNT122, mRNA-4157). On the other hand, biontech is also actively developing fixed-antigen tumor mRNA vaccines, including HPV vaccine BNT113 and melanoma vaccine BNT111. In terms of clinical strategy, biontech's personalized new antigen vaccines are mainly used for adjuvant therapy of early-stage tumors to prevent postoperative recurrence, while fixed antigen vaccines are used for the treatment of late-stage tumors.